Hyperactivation mutations of the PI3K–AKT–mTOR signaling pathway are observed in many cancers, including NSCLC, where they have been heavily implicated in carcinogenesis and disease progression. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.